Delivery Order SPE2DB22D2006-SPE2DB25FW4FB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $5,956.09 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This competitive award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.67 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count packaging). This contract, awarded on August 19, 2025, with a completion date of August 20, 2025, utilizes firm fixed pricing and was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (100-count unit dose packaging) valued at $7,203.47 under a firm fixed-price contract type. The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025, and does not utilize a set-aside designation. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,049.41 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count) with a completion date of August 14, 2025. This firm fixed-price delivery order, issued without a set-aside designation through competitive procurement, represents a routine pharmaceutical supply transaction under the company's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $17,056.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count units), with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract was issued on September 15, 2025, with performance to take place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,033.29 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $14,373.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (500 count) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,812.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and carries an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4FBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,950.66 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This firm fixed price delivery order, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a competitively awarded non-set-aside contract executed under an existing indefinite delivery vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's $999.999 billion indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, which runs through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor that supplies an extensive portfolio of medications and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Ondansetron HCL supply supports medical readiness by providing antiemetic medication for use across military and federal healthcare facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 9/15/25 |